Details for Patent: 8,906,847
✉ Email this page to a colleague
Which drugs does patent 8,906,847 protect, and when does it expire?
Patent 8,906,847 protects YORVIPATH and is included in one NDA.
This patent has thirty-one patent family members in twenty-two countries.
Drugs Protected by US Patent 8,906,847
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-001 | Aug 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS | ⤷ Sign Up | ||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-002 | Aug 9, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS | ⤷ Sign Up | ||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-003 | Aug 9, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF HYPOPARATHYROIDISM IN ADULTS | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,906,847
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009209565 | ⤷ Sign Up | |||
| Brazil | PI0906643 | ⤷ Sign Up | |||
| Canada | 2712224 | ⤷ Sign Up | |||
| China | 101980725 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
